A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Erlotinib (Primary) ; Onalespib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Oct 2017 Status changed from suspended to recruiting.
- 17 Aug 2017 Planned number of patients changed from 52 to 46.
- 17 Aug 2017 Status changed from recruiting to suspended.